Por favor, use este identificador para citar o enlazar este ítem: https://hdl.handle.net/10495/38604
Registro completo de metadatos
Campo DC Valor Lengua/Idioma
dc.contributor.authorConsuegra Asprilla, Jeiser Marcelo-
dc.contributor.authorRodríguez Echeverri, Carolina-
dc.contributor.authorGómez Giraldo, Beatriz Lucía-
dc.contributor.authorGonzález Marín, Ángel Augusto-
dc.contributor.conferencenameTrends in Medical Mycology (11 : Del 20 y 23 de octubre de 2023 : Atenas, Grecia)spa
dc.date.accessioned2024-03-18T19:56:50Z-
dc.date.available2024-03-18T19:56:50Z-
dc.date.issued2023-10-21-
dc.identifier.urihttps://hdl.handle.net/10495/38604-
dc.description.abstractABSTRACT: Vulvovaginal candidiasis (VVC) is the second cause associated with genital tract infections; Approximately 75% of the female population will suffer from VVC at least once in their life (1,2). It is estimated that 138 million people worldwide have recurrent vulvovaginal candidiasis (RVVC), which is defined as four or more episodes of VVC in one year (3,4). This condition is mainly caused by C. albicans, although an increase in other species has been reported. Among the different risk factors associated with the development of RVVC, the following are described: pregnancy, use of therapy with broad-spectrum antibiotics and steroids, hormone replacement therapy, genetic mechanisms, immune (HIV, uncontrolled diabetes and other underlying diseases) and some hygiene, behavioral and idiopathic habits. A failure in the natural or primary immune response is also considered a predisposing factor for suffering RVVC, when the patient does not present any of the aforementioned factors (5).spa
dc.format.mimetypeapplication/pdfspa
dc.language.isoengspa
dc.type.hasversioninfo:eu-repo/semantics/publishedVersionspa
dc.rightsinfo:eu-repo/semantics/openAccessspa
dc.rightsAtribución-NoComercial-CompartirIgual 2.5 Colombia*
dc.rights.urihttp://creativecommons.org/licenses/by-nc-sa/2.5/co/*
dc.titleRecurrent vulvovaginal candidiasis in Colombian women: Main clinical and microbiological characteristicsspa
dc.typeinfo:eu-repo/semantics/workingPaperspa
dc.publisher.groupGrupo de Investigación en Microbiología Básica y Aplicada-Microbaspa
oaire.versionhttp://purl.org/coar/version/c_970fb48d4fbd8a85spa
dc.rights.accessrightshttp://purl.org/coar/access_right/c_abf2spa
oaire.citationtitle11th Trends in Medical Mycologyspa
oaire.citationconferenceplaceAtenas, Greciaspa
dc.rights.creativecommonshttps://creativecommons.org/licenses/by-nc-sa/4.0/spa
dc.type.coarhttp://purl.org/coar/resource_type/c_6670spa
dc.type.redcolhttps://purl.org/redcol/resource_type/ECspa
dc.type.localPóster de conferenciaspa
dc.subject.decsCandidiasis Vulvovaginal-
dc.subject.decsCandidiasis, Vulvovaginal-
dc.subject.decsInfecciones del Sistema Genital-
dc.subject.decsReproductive Tract Infections-
dc.description.researchgroupidCOL0126131spa
dc.subject.meshurihttps://id.nlm.nih.gov/mesh/D002181-
dc.subject.meshurihttps://id.nlm.nih.gov/mesh/D060737-
Aparece en las colecciones: Documentos de conferencias en Microbiología

Ficheros en este ítem:
Fichero Descripción Tamaño Formato  
ConsuegraJeiser_2023_Vulvovaginal_Candidiasis_Colombia.pdfPóster de conferencia887.05 kBAdobe PDFVisualizar/Abrir


Este ítem está sujeto a una licencia Creative Commons Licencia Creative Commons Creative Commons